The β-catenin-dependent Wnt transcriptional activation complex, also known as the Wnt enhanceosome, is probably the most promising drug target for therapeutic intervention in cancers driven by inactivating APC or activating β-catenin mutations3,4. Here, APC is linked to cancer.